|
|
|
Volumn 5, Issue 2, 1999, Pages 243-268
|
|
Multiple-drug-resistant tuberculosis
|
|
Author keywords
Directly observed therapy; Human immunodeficiency virus; Multiple drug resistant tuberculosis
|
|
Indexed keywords
AMIKACIN;
AMINOSALICYLIC ACID;
AZITHROMYCIN;
BENZOXAZINORIFAMYCIN;
CAPREOMYCIN;
CIPROFLOXACIN;
CLARITHROMYCIN;
CYCLOSERINE;
CYTOKINE;
ETHAMBUTOL;
ETHIONAMIDE;
IMMUNOMODULATING AGENT;
ISONIAZID;
MACROLIDE;
OFLOXACIN;
PYRAZINAMIDE;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
RIFABUTIN;
RIFAMPICIN;
RIFAMYCIN;
RIFAMYCIN DERIVATIVE;
RIFAPENTINE;
STREPTOMYCIN;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DISEASE CONTROL;
DRUG ABSORPTION;
DRUG SENSITIVITY;
EARLY DIAGNOSIS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LUNG DISEASE;
MULTIDRUG RESISTANCE;
PATIENT COMPLIANCE;
PREVALENCE;
PRIORITY JOURNAL;
PUBLIC HEALTH;
REVIEW;
RISK FACTOR;
TUBERCULOSIS;
WORLD HEALTH ORGANIZATION;
|
|
EID: 0032721483
PISSN: 10716564
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (5)
|
|
References (14)
|
